newsfilter
← Latest News
Business Wire·

Pathos AI Announces Strategic Collaborations with Bristol Myers Squibb and Tempus AI to Advance AI-Driven Drug Development Beginning with Alzheimer’s Disease and Other Neurological Conditions

Tempus to build a de-identified dataset from hundreds of thousands of patients with neurological conditions; Pathos to license the dataset under a five-year, $55 million agreement Pathos’s AI expertise and agentic